Almost every materials-and-methods draft eventually contains a line such as “the peptide was supplied at ≥99% purity, as determined by HPLC”. It reads as settled fact. In practice it is a summary of a supplier’s testing programme rather than a description of the vial on the bench, and it hides a series of assumptions — about the chromatographic method, the sample, the integration settings and the batch — that a careful referee will want made explicit. Before the draft is circulated, that figure deserves to be converted from a catalogue headline into a documentable, batch-linked statement that a reviewer can trace to a certificate.
What “Typically ≥99%” Is Actually Describing
The word typically is doing a great deal of work in that sentence. It signals an expected or usual value across production runs, not a measured result for one specific lot. As of March 2026, Research Sciences publishes “≥99% Verified Purity” and “UK Research Materials Over 99.1% Purity” as headline figures on its homepage, and its FAQs describe research peptides as typically supplied at ≥99% purity (HPLC tested), with the exact purity stated on the batch Certificate of Analysis. Those are the shop’s current published statements. They should be reconfirmed on the live site and, more importantly, replaced in the manuscript by the figure recorded on the CoA that accompanies the actual batch.
An HPLC purity of ≥99% normally means area percentage at a stated detection wavelength — commonly in the 210–220 nm region for peptides. That is a statement about how much of the UV-absorbing material integrated within the run was assigned to the main peak. It is not a statement of identity, and it is not a statement about non-chromatophoric impurities, residual solvents, water content, counter-ion, heavy metals or endotoxin. Research Sciences describes a full-spectrum testing framework covering purity, identity, heavy metals and endotoxin evaluation of submitted samples, with CoAs linked to supported products. A manuscript should cite only those determinations actually documented for its batch, rather than assuming the whole panel applies by default.
Formulation context matters too. The shop’s FAQs state that all peptides contain trace amounts of mannitol as an excipient, added to aid lyophilisation and storage. The material is therefore a formulated, lyophilised research powder, not neat peptide. Language such as “pure peptide” is imprecise; “peptide-related peak area ≥99% under the stated HPLC conditions” is defensible, provided the excipient is described alongside it.
Finally, the number is method-dependent. Change the column chemistry, the gradient, the ion-pairing agent or the detection wavelength and the area percentage will move, sometimes by a percentage point or more. A figure quoted without its method is a figure that cannot be reproduced, and irreproducible numbers are exactly what reviewers query.
Method Details a Referee Will Expect Behind the Number
If the draft says “≥99% by HPLC”, the reviewer’s immediate question is: which HPLC? The methods section should record the column chemistry and dimensions (for example C18, particle size and length), the mobile phase composition including any ion-pairing modifier such as trifluoroacetic acid, the full gradient table, flow rate, column temperature, detection wavelength, injection volume and total run time. Integration parameters deserve the same treatment: minimum peak area, smoothing, ignore limit, and whether purity was calculated by simple area normalisation, by normalisation excluding specified peaks, or against an external reference standard. Each of these choices can shift a result across the 99% line, and stating them costs a sentence or two.
Identity should be separated from purity in the text. A purity percentage says nothing about whether the main peak is the intended sequence; that requires orthogonal evidence such as mass spectrometry confirmation and, where available, retention-time agreement with a reference standard. The CoA should state which identity method was used, and the draft should mirror that wording rather than infer it.
Mass balance is the next layer. Sample concentration and diluent, water content, counter-ion form (acetate versus trifluoroacetate, for instance) and residual solvent all influence how an area percentage translates into a description of the material. Where the CoA does not report a parameter, say so plainly in the draft instead of implying it was measured.
Handling statements belong in the same paragraph as the material description. The shop’s FAQ guidance is that lyophilised peptides are stored at −20 °C or below, sealed with desiccant and protected from moisture, heat and light, with repeated freeze–thaw cycles avoided; reconstituted material is less stable and is kept at 2–8 °C for short-term laboratory use. Reconstitution volumes should be expressed as diluent volume and target concentration for the specific in-vitro assay, nothing more; the supplier’s reconstitution calculator is a laboratory tool only, and all materials are not for human or veterinary use. Where a draft cites a catalogue page rather than a certificate — for instance when the material was selected from a UK research catalogue where laboratories Buy peptides and preparation tools for in-vitro studies — the figure should be flagged as provisional until the batch CoA is attached.
Batch Traceability, Labelling and the Supporting Paper Trail
Every purity claim in a manuscript should be traceable to one document. Vial labels use a reference format combining SKU code and expiry date, for example BPC10-03/27, which links to the corresponding CoA. Quoting that reference when querying documentation, and reproducing it in the draft’s material-identification table, gives a reviewer a route back to the source. It also prevents the common error of quoting a certificate from an earlier purchase against a later delivery.
That risk is real, because the shop’s FAQs note that restocked products may carry the same Internal Test Reference (ITR) as earlier stock. An ITR links to associated sample testing reports; it does not confirm that separate deliveries come from the same production lot or that they have been independently tested separately. Matching ITRs are therefore not evidence that a certificate describes the vial in hand. Request the CoA corresponding to the actual delivery, and treat vial cap colour and other packaging variation as irrelevant to identity, analytical quality or manufacturing origin.
Where the homepage lists “CoAs Janoshik Analytical Reports”, that is a statement about the documentation the shop publishes — open and check the CoA that accompanies the specific batch rather than relying on the headline. The same discipline applies to any published figure, including order counts or delivery estimates, which should be reconfirmed against current site wording before appearing anywhere in a paper. Delivery timings are estimates influenced by peak periods and do not belong in a methods section at all.
Compliance language should be precise and attributed. Products are labelled “For Research Use Only – Not for Human Consumption”, a position the shop describes as being in line with MHRA guidance; present that as the supplier’s stated position rather than as legal advice. The draft should record that the purchaser is responsible for lawful use, safe handling, storage and disposal, for compliance with COSHH and laboratory safety standards, and for confirming that the material suits the intended in-vitro application. A sentence such as “the lyophilised research peptide (batch reference BPC10-03/27) was supplied with a batch CoA reporting ≥99% purity by reversed-phase HPLC at 214 nm, with identity confirmed by mass spectrometry, and was stored at −20 °C under desiccant before reconstitution in assay diluent” replaces the vague original and gives a referee everything needed to audit the claim.
Pune-raised aerospace coder currently hacking satellites in Toulouse. Rohan blogs on CubeSat firmware, French pastry chemistry, and minimalist meditation routines. He brews single-origin chai for colleagues and photographs jet contrails at sunset.
